Celltrion has acquired exclusive global development and commercialisation rights to Kaigene's investigational monoclonal antibody, KG013, in a deal worth up to $580m.

Boehringer Ingelheim and Microsoft have entered into a strategic collaboration to examine the use of AI in clinical research, beginning with studies in lung health.

AI Proteins and Astellas Innovation Management have signed a research collaboration and licence deal to discover and develop miniprotein therapeutics.

Fenwick partners Chelsea Anderson and Noah Solowiejczyk outline how prediction markets will impact how biotechs operate.

Following its provisional blessing in IgAN, AstraZeneca's Ultomiris is now indicated for use in six conditions.

Explore retatrutide peptide quality control, including batch testing and supplier documentation checks for laboratory research.

GSK's likely blockbuster-to-be led to a fifth of patients having undetectable viral levels in clinical trials.

At CPHI Milan 2026, pharma leaders examined how AI can accelerate formulation, process development, maintenance, and quality management—without compromising data security or human oversight.

Ambrose will now enter the race to debut a new medicine on the HPP market as the only approved therapy edges closer to key patent expiries.

The FDA has granted approval for Cosette’s Evoxac oral solution to treat dry mouth symptoms in adults diagnosed with Sjögren’s disease.

UK children at risk of anaphylaxis could soon have another treatment option available at school, after the Medicines and Healthcare products Regulatory Agency (MHRA) said it would consider allowing ...

This deal sees Gilead double down on TCEs, following its first bet on the modality through its buyout of autoimmune-focused Ouro Medicines.